1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6677702EE24835EEF852584B10027FC71
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/677702EE24835EEF852584B10027FC71?OpenDocument
18
19OpenDocument
203.233.242.204
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Science Liaison

Document Excerpt: Raising Phase IV Performance & Value Through Optimal MSL Involvement: Objectives & Team Structure

DB Image

Excerpt in Cart

ID: MD-685


Features:

8 Info Graphics

10 Data Graphics

160+ Metrics

4 Narratives


Pages/Slides: 4


Published: 2019


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5585 "Raising Phase IV Performance & Value Through Optimal MSL Involvement: Objectives & Team Structure”.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Health Care


Companies Profiled:
AbbVie; Alkermes; BeiGene; BioDelivery Sciences International; Inc.; Biogen; BioMarin; BTG plc; Cipla; Eisai; EMD Serono; Impel NeuroPharma; Intas; Ipsen; Janssen; La Jolla Pharmaceutical; Mayne; Melinta Therapeutics; Inc; Merck; Merck KGaA; Milestone Pharmaceuticals; Myriad Genetics; Novartis; Pfizer; Rakuten Medical; Searle; Shire; Sunovion; Taiho Pharma; Takeda Pharmaceuticals; UniQure; Vifor Pharma

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.